Volume 134, Issue 4 pp. 1008-1012
Short Report

Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas

Netta Mäkinen

Netta Mäkinen

Department of Medical Genetics, Genome-Scale Biology Research Program, University of Helsinki, Helsinki, Finland

Search for more papers by this author
Pia Vahteristo

Pia Vahteristo

Department of Medical Genetics, Genome-Scale Biology Research Program, University of Helsinki, Helsinki, Finland

Search for more papers by this author
Ralf Bützow

Ralf Bützow

Department of Pathology, Haartman Institute and HUSLAB, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland

Search for more papers by this author
Jari Sjöberg

Jari Sjöberg

Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland

Search for more papers by this author
Lauri A. Aaltonen

Corresponding Author

Lauri A. Aaltonen

Department of Medical Genetics, Genome-Scale Biology Research Program, University of Helsinki, Helsinki, Finland

Correspondence to: Lauri A. Aaltonen, MD, PhD, Academy Professor, Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, P.O. Box 63 (Haartmaninkatu 8), 00014 Helsinki, Finland, Tel.: +358-9-19125595, Fax: +358-9-19125105, E-mail: [email protected]Search for more papers by this author
First published: 03 August 2013
Citations: 32

Conflict of interest: Nothing to report

Abstract

Uterine leiomyomas are extremely common tumors originating from the smooth muscle cells of myometrium. We recently reported recurrent somatic mutations in mediator complex subunit 12 (MED12) in the majority of these lesions, and analyzed chromosomal abnormalities in leiomyomas by whole-genome sequencing. The aim of our study was to examine in detail uterine leiomyoma exomes, to search for driver mutations in MED12 mutation-negative leiomyomas and to scrutinize MED12 mutation-positive leimyomas for additional contributing mutations. We analyzed whole exome sequencing data of 27 uterine leiomyomas (12 MED12 mutation-negative and 15 MED12 mutation-positive) and their paired normal myometrium. We searched for genes, which would be recurrently mutated. No such genes were identified in MED12 mutation-negative uterine leiomyomas. Similarly, MED12 mutation-positive leiomyomas displayed no additional recurrent changes. The complete lack of novel driver point mutations in the examined series highlights the unique role of MED12 mutations in genesis of uterine leiomyomas, and suggests that these mutations alone may be sufficient for tumor development. Additional factors that cannot be detected by exome sequencing, such as somatic structural rearrangements, epigenetic events and intronic variants, are likely to have a particular impact to the development of MED12 wild-type lesions.

Abstract

What's new?

Nearly 70 percent of women develop uterine leiomyomas, or fibroids, by age 50. While benign, these tumors are associated with a high incidence of conditions that adversely affect the pelvis and reproductive system. Despite their prevalence and morbidity, however, little is known about the mechanisms behind uterine leiomyoma formation. Whole exome sequencing of MED12 mutation-negative and mutation-positive uterine leiomyomas performed in this study reveals that these tumors do not carry recurrent mutations in genes other than MED12. The findings suggest that MED12 mutations alone may be sufficient for tumor development and shed light on benign tumorigenesis.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.